Pure Extracts Technologies Past Earnings Performance
Past criteria checks 0/6
Pure Extracts Technologies's earnings have been declining at an average annual rate of -8.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 128.2% per year.
Key information
-8.2%
Earnings growth rate
44.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 128.2% |
| Return on equity | -815.9% |
| Net Margin | -244.8% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pure Extracts Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 2 | -5 | 3 | 0 |
| 30 Sep 22 | 2 | -5 | 4 | 0 |
| 30 Jun 22 | 1 | -5 | 4 | 0 |
| 31 Mar 22 | 1 | -6 | 5 | 0 |
| 31 Dec 21 | 1 | -11 | 10 | 0 |
| 30 Sep 21 | 0 | -21 | 16 | 0 |
| 30 Jun 21 | 0 | -21 | 16 | 0 |
| 31 Mar 21 | 0 | -19 | 15 | 0 |
| 31 Dec 20 | 0 | -14 | 9 | 0 |
| 30 Sep 20 | 0 | -4 | 2 | 0 |
| 30 Jun 20 | 0 | -3 | 2 | 0 |
Quality Earnings: PUX is currently unprofitable.
Growing Profit Margin: PUX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PUX is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.
Accelerating Growth: Unable to compare PUX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PUX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: PUX has a negative Return on Equity (-815.88%), as it is currently unprofitable.